Squarepoint
CGTX icon

Squarepoint’s Cognition Therapeutics CGTX Stock Holding History

Squarepoint’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.2K Buy
26,546
+16,153
+155% +$18.8K ﹤0.01% 4174
2025
Q4 		$14K Buy
+10,393
New +$16.9K ﹤0.01% 4179

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Squarepoint's CGTX Position: Q1 2026 in Review

Squarepoint increased its Cognition Therapeutics (CGTX) stake by 155% in Q1 2026, buying an estimated $18.8K and bringing the position to 26,546 shares worth $20.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4174.

Squarepoint first reported a position in CGTX in Q4 2025 and has held it in 2 quarters since. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Squarepoint held 26,546 shares of Cognition Therapeutics worth $20.2K as of Q1 2026.
  • Squarepoint bought 16,153 Cognition Therapeutics shares in Q1 2026, an estimated $18.8K.
  • Cognition Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4174 holding.
  • Squarepoint first reported a position in Cognition Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.